|Source||Humanized (from mouse)|
|Molecular mass||148 kDa|
|(what is this?)|
Ocrelizumab is a humanized anti-CD20 monoclonal antibody, hence a CD20 antagonist. It targets mature B lymphocytes and hence is an immunosuppressive drug candidate. It is under development for multiple sclerosis by Hoffmann–La Roche's subsidiary Genentech, and Biogen Idec.
In March 2010, Roche announced the suspension of clinical trials in rheumatoid arthritis and lupus erythematosus. This step followed excess deaths due to opportunistic infections. Development for multiple sclerosis continues.
In October 2010, Roche announced 24-week results from the PhII study in relapsing-remitting MS. The drug demonstrated a statistically significant reduction in disease activity as measured by brain lesions (measured by MRI scans) and relapse rate compared to placebo. Both doses (200 mg and 600 mg) were well tolerated.
Ocrelizumab is a slightly modified version of Biogen/Genentech's existing therapy Rituxan/Rituximab. As Rituxan was approaching FDA approval for treatment of multiple sclerosis, it was simultaneously approaching the end of its patent. To avoid the profit loss of a new treatment that could have been available sooner and eventually in a generic form, Rituxan trials were halted and Ocrelizumab trials quickly began.
- Other CD20 antagonists:
- BIIB033 (Anti-LINGO-1): another monoclonal antibody designed for treating multiple sclerosis
- K. John Morrow Jr (2008-06-15). "Methods for Maximizing Antibody Yields". Genetic Engineering & Biotechnology News (Mary Ann Liebert, Inc.). p. 36. Retrieved 2008-07-06. (Note: information included in this article only found in table present in print version of article.)
- Kausar, F; Mustafa, K; Sweis, G; Sawaqed, R; Alawneh, K; Salloum, R; Badaracco, M; Niewold, TB; Sweiss, NJ (2009). "Ocrelizumab: a step forward in the evolution of B-cell therapy". Expert opinion on biological therapy 9 (7): 889–95. doi:10.1517/14712590903018837. PMID 19463076.
- Clinical trial number NCT00539838 for "A Study to Evaluate Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus (BEGIN)" at ClinicalTrials.gov
- Clinical trial number NCT00676715 for "A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis" at ClinicalTrials.gov
- Hutas, G (2008). "Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell malignancies". Current opinion in investigational drugs (London, England : 2000) 9 (11): 1206–15. PMID 18951300.
- Katie Reid (2010-03-08). Update 2. Roche suspends arthritis treatment after deaths. Reuters. Retrieved 2010-03-08.
- First Data From Ocrelizumab Phase 3 Studies in MS. Oct 2015
- In Third Trial, Ocrelizumab Shows Promise in Progressive MS
- The shameful story of Rituximab in Multiple Sclerosis
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|